วัคซีนเดงกี่

Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Baerberousse C, Innis B, et al. Safety and immunogenicity of a tetravalent live- attenuated dengue vaccine in flavivirus naïve children.Am J Trop Med Hyg. 2008;78:426-33.

Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL, et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. Am J Trop Med Hyg. 2011;85:341-51.

Watanaveeradej V, Gibbons RV, Simasathien S, Nisalak A, Jarman RG, Kerdpanich A, et al. Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial. Am J Trop Med Hyg. 2014;91:119-28.

Moris P, Bauer KM, Currier JR, Friberg H, Eckels KH, Esquilin IO, et al. Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions. Hum Vaccin Immunother. 2019;15:2090-105.

Pintado Silva J, Fenutria R, Bernal-Rubio D, Sanchez-Martin I, Hunziker A, Chebishev E, et al. The dengue virus 4 component of NIAID's tetravalent TV003 vaccine drives its innate immune signature. Exp Biol Med (Maywood). 2022;247:2201-12.

Rosa BR, Ledo Alves da Cunha AJ , de Andrade Medronho R. Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2-17 years: systematic review and meta-analysis. BMJ Open. 2019;9:e019368.

Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379:327-40.

Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, et al; TIDES Study Group. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. N Engl J Med. 2019;381:2009-19.

Biswal S, Borja-Tabora C, Martinez Vargas L, Velásquez H, Theresa Alera M, Sierra V, et al; TIDES study group. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. Lancet. 2020;395:1423-33.

Tricou V, Yu D, Reynales H, Biswal S, Saez-Llorens X, Sirivichayakul C, et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 2024;12:e257-e270.

LeFevre I, Bravo L, Folschweiller N, Medina EL, Moreira ED Jr, Nordio F, et al. Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults. NPJ Vaccines. 2023;8:75.

Butantan's dengue vaccine has 79.6% efficacy, partial results from 2-year follow-up. [Cited 26 Jun 2024]. Available from: https://butantan.gov.br/noticias/butantan%27s-dengue-vaccine-has-79.6-efficacy-partial-results-from-2-year-follow-up-show

กองโรคติดต่อนำโดยแมลง. รวมสถานการณ์โรคติดต่อนำโดยแมลงย้อนหลัง. กรมควบคุมโรค กระทรวงสาธารณสุข. [Cited 26 Jun 2024]. Available from: https://ddc.moph.go.th/dvb/